<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Briacell Therapeutics Corp — News on 6ix</title>
    <link>https://6ix.com/company/briacell-therapeutics-corp</link>
    <description>Latest news and press releases for Briacell Therapeutics Corp on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Mon, 27 Apr 2026 11:30:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/briacell-therapeutics-corp" rel="self" type="application/rss+xml" />
    <item>
      <title>BriaCell Announces Six Clinical Data Presentations at ASCO 2026</title>
      <link>https://6ix.com/company/briacell-therapeutics-corp/news/briacell-announces-six-clinical-data-presentations-at-asco-2026</link>
      <guid isPermaLink="true">https://6ix.com/company/briacell-therapeutics-corp/news/briacell-announces-six-clinical-data-presentations-at-asco-2026</guid>
      <pubDate>Mon, 27 Apr 2026 11:30:00 GMT</pubDate>
      <description>Final randomized Phase 2 Bria-IMT™ survival and quality of life data to be presentedBiomarker analyses from the ongoing Phase 3 study evaluating predictors of response PHILADELPHIA and VANCOUVER, British Columbia, April 27, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, is pleased to announce three clinical data poster presentatio</description>
    </item>
    <item>
      <title>BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+(TM) in Preclinical Cancer Models</title>
      <link>https://6ix.com/company/briacell-therapeutics-corp/news/briacell-presents-robust-anti-cancer-activity-of-bria-otstm-in-preclinical-cancer-models</link>
      <guid isPermaLink="true">https://6ix.com/company/briacell-therapeutics-corp/news/briacell-presents-robust-anti-cancer-activity-of-bria-otstm-in-preclinical-cancer-models</guid>
      <pubDate>Tue, 21 Apr 2026 11:30:00 GMT</pubDate>
      <description>Bria-OTS+ platform provides early, potent and durable activation of innate and adaptive immunity ...</description>
    </item>
    <item>
      <title>BriaCell Presents Positive Phase 3 Quality of Life and Phase 2 Biomarker Data at the 2026 AACR Meeting</title>
      <link>https://6ix.com/company/briacell-therapeutics-corp/news/briacell-presents-positive-phase-3-quality-of-life-and-phase-2-biomarker-data-at-the-2026-aacr-meeting</link>
      <guid isPermaLink="true">https://6ix.com/company/briacell-therapeutics-corp/news/briacell-presents-positive-phase-3-quality-of-life-and-phase-2-biomarker-data-at-the-2026-aacr-meeting</guid>
      <pubDate>Mon, 20 Apr 2026 11:30:00 GMT</pubDate>
      <description>Phase 3 clinical data in heavily pretreated metastatic breast cancer patients with prior failed A...</description>
    </item>
    <item>
      <title>BriaCell and BriaPro Announce Closing of Asset Purchase Transaction for Exclusive Soluble CD80 License</title>
      <link>https://6ix.com/company/briacell-therapeutics-corp/news/briacell-and-briapro-announce-closing-of-asset-purchase-transaction-for-exclusive-soluble-cd80-license</link>
      <guid isPermaLink="true">https://6ix.com/company/briacell-therapeutics-corp/news/briacell-and-briapro-announce-closing-of-asset-purchase-transaction-for-exclusive-soluble-cd80-license</guid>
      <pubDate>Tue, 31 Mar 2026 20:05:06 GMT</pubDate>
      <description>PHILADELPHIA and VANCOUVER, British Columbia, March 31, 2026 (GLOBE NEWSWIRE) -- BriaCell Therape...</description>
    </item>
    <item>
      <title>BriaCell to Present Positive Clinical Data for Bria-IMT(TM) and Preclinical Data for Next Generation Bria-OTS+(TM) Personalized Immunotherapy at the 2026 AACR Conference</title>
      <link>https://6ix.com/company/briacell-therapeutics-corp/news/briacell-to-present-positive-clinical-data-for-bria-imttm-and-preclinical-data-for-next-generation-bria-otstm-personalized-immunotherapy-at-the-2026-aacr-conference</link>
      <guid isPermaLink="true">https://6ix.com/company/briacell-therapeutics-corp/news/briacell-to-present-positive-clinical-data-for-bria-imttm-and-preclinical-data-for-next-generation-bria-otstm-personalized-immunotherapy-at-the-2026-aacr-conference</guid>
      <pubDate>Wed, 18 Mar 2026 11:30:00 GMT</pubDate>
      <description>PHILADELPHIA and VANCOUVER, British Columbia, March 18, 2026 (GLOBE NEWSWIRE) -- BriaCell Therape...</description>
    </item>
    <item>
      <title>BriaCell to Present Positive Clinical Data for Bria-IMT™ and Preclinical Data for Next Generation Bria-OTS+™ Personalized Immunotherapy at the 2026 AACR Conference</title>
      <link>https://6ix.com/company/briacell-therapeutics-corp/news/briacell-to-present-positive-clinical-data-for-bria-imttm-and-preclinical-data-for-next-generation-bria-otstm-personalized-immunotherapy-at-the-2026-aacr-conference-1</link>
      <guid isPermaLink="true">https://6ix.com/company/briacell-therapeutics-corp/news/briacell-to-present-positive-clinical-data-for-bria-imttm-and-preclinical-data-for-next-generation-bria-otstm-personalized-immunotherapy-at-the-2026-aacr-conference-1</guid>
      <pubDate>Wed, 18 Mar 2026 11:30:00 GMT</pubDate>
      <description>PHILADELPHIA and VANCOUVER, British Columbia, March 18, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, announces that it will present four posters at the 2026 American Association for Cancer Research (AACR) Annual Meeting, taking place April 17–22 at the San Diego Convention Center in San Diego, California. The presentations will</description>
    </item>
    <item>
      <title>BriaCell to Present Four Poster Presentations at the 2026 AACR Annual Meeting</title>
      <link>https://6ix.com/company/briacell-therapeutics-corp/news/briacell-to-present-four-poster-presentations-at-the-2026-aacr-annual-meeting-3</link>
      <guid isPermaLink="true">https://6ix.com/company/briacell-therapeutics-corp/news/briacell-to-present-four-poster-presentations-at-the-2026-aacr-annual-meeting-3</guid>
      <pubDate>Tue, 10 Mar 2026 11:30:00 GMT</pubDate>
      <description>PHILADELPHIA and VANCOUVER, British Columbia, March 10, 2026 (GLOBE NEWSWIRE) -- BriaCell Therape...</description>
    </item>
    <item>
      <title>BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting</title>
      <link>https://6ix.com/company/briacell-therapeutics-corp/news/briacell-therapeutics-corp-announces-results-of-shareholder-meeting-47</link>
      <guid isPermaLink="true">https://6ix.com/company/briacell-therapeutics-corp/news/briacell-therapeutics-corp-announces-results-of-shareholder-meeting-47</guid>
      <pubDate>Thu, 05 Mar 2026 21:04:34 GMT</pubDate>
      <description>PHILADELPHIA and VANCOUVER, British Columbia, March 05, 2026 (GLOBE NEWSWIRE) --  BriaCell Therap...</description>
    </item>
    <item>
      <title>BriaCell and BriaPro Enter Into Asset Purchase Agreement for Exclusive Soluble CD80 License</title>
      <link>https://6ix.com/company/briacell-therapeutics-corp/news/briacell-and-briapro-enter-into-asset-purchase-agreement-for-exclusive-soluble-cd80-license</link>
      <guid isPermaLink="true">https://6ix.com/company/briacell-therapeutics-corp/news/briacell-and-briapro-enter-into-asset-purchase-agreement-for-exclusive-soluble-cd80-license</guid>
      <pubDate>Wed, 18 Feb 2026 22:30:00 GMT</pubDate>
      <description>PHILADELPHIA and VANCOUVER, British Columbia, Feb. 18, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ, BCTXL) (TSX: BCT) (“BriaCell”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, and its majority-owned subsidiary, BriaPro Therapeutics Corp. (“BriaPro”), are pleased to announce that they have entered into a definitive purchase agreement (the “Purchase Agreement”) pursuant to which BriaPro has agreed to purc</description>
    </item>
    <item>
      <title>BriaCell Patients’ Images Show Regression and Resolution of Metastasized Tumors and Immune Activation</title>
      <link>https://6ix.com/company/briacell-therapeutics-corp/news/briacell-patients-images-show-regression-123000407</link>
      <guid isPermaLink="true">https://6ix.com/company/briacell-therapeutics-corp/news/briacell-patients-images-show-regression-123000407</guid>
      <pubDate>Wed, 28 Jan 2026 12:30:00 GMT</pubDate>
      <description>Images below confirm clinical responses seen in patients with metastatic orbital (eye), temporal (brain), liver, and spine lesions No Bria-IMT™ related discontinuations reported to dateBria-IMT regimen continues under Fast Track Designation from US FDA PHILADELPHIA and VANCOUVER, British Columbia, Jan. 28, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immun</description>
    </item>
    <item>
      <title>BriaCell Patients&apos; Images Show Regression and Resolution of Metastasized Tumors and Immune Activation</title>
      <link>https://6ix.com/company/briacell-therapeutics-corp/news/briacell-patients-images-show-regression-and-resolution-of-metastasized-tumors-and-immune-activation</link>
      <guid isPermaLink="true">https://6ix.com/company/briacell-therapeutics-corp/news/briacell-patients-images-show-regression-and-resolution-of-metastasized-tumors-and-immune-activation</guid>
      <pubDate>Wed, 28 Jan 2026 12:30:00 GMT</pubDate>
      <description>Images below confirm clinical responses seen in patients with metastatic orbital (eye), temporal ...</description>
    </item>
    <item>
      <title>BriaCell Highlights Extended &gt;18-47 Months Survival in Phase 2 Metastatic Breast Cancer Patients</title>
      <link>https://6ix.com/company/briacell-therapeutics-corp/news/briacell-highlights-extended-18-47-123000147</link>
      <guid isPermaLink="true">https://6ix.com/company/briacell-therapeutics-corp/news/briacell-highlights-extended-18-47-123000147</guid>
      <pubDate>Tue, 27 Jan 2026 12:30:00 GMT</pubDate>
      <description>9 of 25 BriaCell patients treated since 2022 remain alive &gt;18-47 months post enrollment, markedly exceeding benchmarks reported for standard of care therapies in similar patient populationsNo Bria-IMT™ related discontinuations reported to dateBria-IMT regimen continues under Fast Track Designation from US FDA PHILADELPHIA and VANCOUVER, British Columbia, Jan. 27, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a c</description>
    </item>
    <item>
      <title>BriaCell Therapeutics Announces Closing of US$30 million Public Offering</title>
      <link>https://6ix.com/company/briacell-therapeutics-corp/news/briacell-therapeutics-announces-closing-of-usdollar30-million-public-offering</link>
      <guid isPermaLink="true">https://6ix.com/company/briacell-therapeutics-corp/news/briacell-therapeutics-announces-closing-of-usdollar30-million-public-offering</guid>
      <pubDate>Thu, 15 Jan 2026 21:05:00 GMT</pubDate>
      <description>PHILADELPHIA and VANCOUVER, British Columbia, Jan. 15, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeu...</description>
    </item>
    <item>
      <title>BriaCell Therapeutics Announces Pricing of $30 million Public Offering</title>
      <link>https://6ix.com/company/briacell-therapeutics-corp/news/briacell-therapeutics-announces-pricing-of-dollar30-million-public-offering</link>
      <guid isPermaLink="true">https://6ix.com/company/briacell-therapeutics-corp/news/briacell-therapeutics-announces-pricing-of-dollar30-million-public-offering</guid>
      <pubDate>Wed, 14 Jan 2026 02:00:22 GMT</pubDate>
      <description>PHILADELPHIA and VANCOUVER, British Columbia, Jan. 13, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeu...</description>
    </item>
    <item>
      <title>BriaCell Reports Sustained Complete Resolution of Lung Metastasis in Bria-OTS™ Patient</title>
      <link>https://6ix.com/company/briacell-therapeutics-corp/news/briacell-reports-sustained-complete-resolution-123000328</link>
      <guid isPermaLink="true">https://6ix.com/company/briacell-therapeutics-corp/news/briacell-reports-sustained-complete-resolution-123000328</guid>
      <pubDate>Tue, 13 Jan 2026 12:30:00 GMT</pubDate>
      <description>[IMAGES BELOW] 11-month sustained complete resolution of lung metastasis observed in Bria-OTS Phase 1/2a metastatic breast cancer study.No treatment limiting toxicities reported.Patient maintained stable disease at all other evaluable sites. PHILADELPHIA and VANCOUVER, British Columbia, Jan. 13, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to tran</description>
    </item>
    <item>
      <title>BriaCell Reports Sustained Complete Resolution of Lung Metastasis in Bria-OTS(TM) Patient</title>
      <link>https://6ix.com/company/briacell-therapeutics-corp/news/briacell-reports-sustained-complete-resolution-of-lung-metastasis-in-bria-otstm-patient</link>
      <guid isPermaLink="true">https://6ix.com/company/briacell-therapeutics-corp/news/briacell-reports-sustained-complete-resolution-of-lung-metastasis-in-bria-otstm-patient</guid>
      <pubDate>Tue, 13 Jan 2026 12:30:00 GMT</pubDate>
      <description>[IMAGES BELOW] 11-month sustained complete resolution of lung metastasis observed in Bria-OTS Pha...</description>
    </item>
    <item>
      <title>How $594B in Precision Tech is Cracking the Metastatic Cancer Code</title>
      <link>https://6ix.com/company/briacell-therapeutics-corp/news/how-dollar594b-in-precision-tech-is-cracking-the-metastatic-cancer-code</link>
      <guid isPermaLink="true">https://6ix.com/company/briacell-therapeutics-corp/news/how-dollar594b-in-precision-tech-is-cracking-the-metastatic-cancer-code</guid>
      <pubDate>Wed, 07 Jan 2026 15:32:00 GMT</pubDate>
      <description>How $594B in Precision Tech is Cracking the Metastatic Cancer Code         Canada NewsWire       ...</description>
    </item>
    <item>
      <title>&quot;Eleven clinical trials that will shape medicine in 2026&quot; - BriaCell Phase 3 Trial Featured in Nature Medicine</title>
      <link>https://6ix.com/company/briacell-therapeutics-corp/news/eleven-clinical-trials-that-will-shape-medicine-in-2026-briacell-phase-3-trial-featured-in-nature-medicine</link>
      <guid isPermaLink="true">https://6ix.com/company/briacell-therapeutics-corp/news/eleven-clinical-trials-that-will-shape-medicine-in-2026-briacell-phase-3-trial-featured-in-nature-medicine</guid>
      <pubDate>Thu, 18 Dec 2025 12:30:00 GMT</pubDate>
      <description>Nature Medicine asked leading researchers to name their top clinical trial for 2026, from long-aw...</description>
    </item>
    <item>
      <title>“Eleven clinical trials that will shape medicine in 2026” – BriaCell Phase 3 Trial Featured in Nature Medicine</title>
      <link>https://6ix.com/company/briacell-therapeutics-corp/news/eleven-clinical-trials-shape-medicine-123000190</link>
      <guid isPermaLink="true">https://6ix.com/company/briacell-therapeutics-corp/news/eleven-clinical-trials-shape-medicine-123000190</guid>
      <pubDate>Thu, 18 Dec 2025 12:30:00 GMT</pubDate>
      <description>Nature Medicine asked leading researchers to name their top clinical trial for 2026, from long-awaited vaccines for infectious diseases to new treatments for advanced cancers and long COVIDBriaCell’s Phase 3 clinical trial in metastatic breast cancer featured as “clinical trial to watch in 2026”BriaCell anticipates reporting top line data as early as H1-2026 PHILADELPHIA and VANCOUVER, British Columbia, Dec. 18, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT</description>
    </item>
    <item>
      <title>BriaCell Presents Outstanding Phase 2 Survival &amp; Promising Phase 3 Clinical Data at SABCS&amp;#xAE; 2025</title>
      <link>https://6ix.com/company/briacell-therapeutics-corp/news/briacell-presents-outstanding-phase-2-survival-and-promising-phase-3-clinical-data-at-sabcsandxae-2025</link>
      <guid isPermaLink="true">https://6ix.com/company/briacell-therapeutics-corp/news/briacell-presents-outstanding-phase-2-survival-and-promising-phase-3-clinical-data-at-sabcsandxae-2025</guid>
      <pubDate>Wed, 10 Dec 2025 12:30:00 GMT</pubDate>
      <description>BriaCell presents positive clinical data in three posters at the San Antonio Breast Cancer Sympos...</description>
    </item>
  </channel>
</rss>